The Massachusetts Radiation Control Program (RCP), in conjunction with the U.S. Nuclear Regulatory Commission (NRC), has approved Alpha Tau Medical’s Alpha DaRT cancer treatment as a Sealed Source and Device (SSD). https://www.dotmed.com/news/story/44162 Granting of the certification deems the radiotherapy solution a suitable candidate for clinical trials at U.S. cancer centers in the treatment of various types of solid tumors. Known as Diffusing Alpha-emitters Radiation Ther

Alpha Tau is in the last stages of raising an investment of several tens of millions of dollars. Israeli oncology company Alpha Tau Medical Ltd. is in the last stages of raising an investment of several tens of millions of dollars, one person familiar with the matter told Calcalist on condition of anonymity. The round is expected to close by the end of the month, that person said. Alpha Tau raised $25 million to date. Cancer tumor (illustration). Photo: medscape Founded in 20

The new Sealed Source and Device (SSD) approval enables the commencement of clinical trials in leading hospitals across the U.S. with the company’s breakthrough cancer treatment, Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy). Boston, MA, August 21st 2018 -- Israel MedTech startup, Alpha Tau Medical, is proud to announce that the Massachusetts Radiation Control Program (RCP), under agreement with the U.S. Nuclear Regulatory Commission (NRC), approved the company’s tr

[..] Another company from Tel Aviv, Alpha Tau Medical, has partnered with Japanese biotechnology startup HekaBio to release radiation therapy equipment in Japan in 2021, at the earliest. The product is designed to treat patients with breast, skin and other solid cancers. Unlike most such equipment, Alpha Tau's "radioactive seeds" emit alpha rays from inside the body. These rays are more powerful than other forms of radiation but are less likely to damage surrounding cells. He